U.S. stock night market fluctuations: Addex Therapeutics rose 7.20% in the night market, with active capital flow attracting market attention

U.S. Stock Night Market Movements Addex Therapeutics rose 7.20% in the night market, with no significant news recently. Trading was active, and capital flows were evident. Considering the sector and industry trends, the stock showed significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry Novo Nordisk rose 0.49% in the night market. Based on recent news, On December 23, the U.S. Food and Drug Administration approved Novo Nordisk's oral weight loss pill Wegovy for market release. This news caused Novo Nordisk's stock price to rise 6.6% in after-hours trading and continue to rise 7.5% in pre-market trading. The weight loss effect of this pill is comparable to that of injections, and it is expected to be available in the U.S. in early January 2026. This event gives Novo Nordisk a competitive advantage in the obesity treatment market. On December 24, Novo Nordisk announced that its oral weight loss pill Wegovy was approved for market release, driving the company's stock price up 7.30%, closing at $51.61. Despite facing competition from Eli Lilly and price reduction restrictions from Trump on pharmaceutical companies, Novo Nordisk's stock price has fallen 38.35% this year. On December 23, Novo Nordisk's CEO stated that the company is "absolutely interested" in pursuing more merger and acquisition deals. This news further boosted market confidence in the company, driving the stock price up. The weight loss drug market is highly competitive, and Novo Nordisk has received approval for a new drug. Amgen rose 0.46% in the night market. Based on recent key news: On December 24, Amgen received FDA approval for its Yartemlea treatment regimen. This drug is the first treatment for thrombotic microangiopathy related to stem cell transplants, and FDA approval makes it the only lectin pathway inhibitor, driving the stock price up. On December 25, D. Boral Capital maintained Amgen's target price at $36 per share, with analysts optimistic about the company's future commercialization prospects, further supporting the stock price increase. On December 25, Stephen Brozak of WBB Securities reiterated a buy rating with a target price of $45, expressing confidence in the company's management team's capabilities, enhancing market confidence. The approval of innovative drugs in the pharmaceutical industry drives the stock price up. Eli Lilly rose 0.14% in the night market. Based on recent news: On December 25, Eli Lilly's innovative drug tirzepatide was officially included in the new national medical insurance catalog, leading to a new round of price reductions in the domestic blood sugar and weight loss drug market. Some online pharmaceutical platforms have already initiated pre-sale activities with a pre-sale price as low as 450 yuan for the 10mg specification, which is about 20% of the previous price. This move is expected to enhance Eli Lilly's competitiveness in the domestic market. On December 24, Novo Nordisk announced that its oral version of the weight loss drug Wegovy received FDA approval, making it the first approved oral weight loss drug. After the announcement, Novo Nordisk's stock price surged 7.3%, while Eli Lilly's stock price slightly fell by 0.45% Novo Nordisk's progress poses a challenge to Eli Lilly's leadership position in the weight loss drug market. On December 23, Eli Lilly announced it would pay $40 million for licensing, research, and collaboration, along with a $15 million equity investment to collaborate with ABL Bio on joint research based on a bispecific antibody platform. This move aims to strengthen its leading position in the biopharmaceutical field through innovative collaboration. The weight loss drug market is highly competitive, with broad industry prospects